If you have been reading about Heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Reversed-phase HPLC retention time versus reference standard | Retention depends on column, gradient, and ion-pairing agent |
| Mass confirmation | Electrospray or MALDI mass spectrometry | Doubly protonated ion near m/z 377 is consistent with about 752 Da |
| Typical purity specification | 95 percent or higher by chromatographic peak area | Lower values suggest truncated or modified peptide species |
| Storage of lyophilized powder | -20 °C, desiccated, protected from light | Powder tolerates long storage better than solution |
| Storage of solution | 2-8 °C for short periods | Freeze-thaw cycling promotes aggregation and surface adsorption |
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
In a systematic review of published evidence, the United States Preventive Services Task Force in 2017 concluded that there was uncertainty about the accuracy or clinical utility of all potential screening tools for OSA, and recommended that evidence is insufficient to assess the balance of benefits and harms of screening for OSA in asymptomatic adults. The diagnosis of OSA syndrome is made when the patient shows recurrent episodes of partial or complete collapse of the upper airway during sleep resulting in apneas or hypopneas, respectively. Criteria defining an apnea or a hypopnea vary. The American Academy of Sleep Medicine (AASM) defines apnea as a reduction in airflow of ≥ 90% lasting at least 10 seconds. A hypopnea is defined as a reduction in airflow of ≥ 30% lasting at least 10 seconds and associated with a ≥ 4% decrease in pulse oxygenation, or as a ≥ 30% reduction in airflow lasting at least 10 seconds and associated either with a ≥ 3% decrease in pulse oxygenation or with an arousal. To define the severity of the condition, the Apnea-Hypopnea Index (AHI) or the Respiratory Disturbance Index (RDI) are used. While the AHI measures the mean number of apneas and hypopneas per hour of sleep, the RDI adds to this measure the respiratory effort-related arousals (RERAs). The OSA syndrome is thus diagnosed if the AHI is > 5 episodes per hour and results in daytime sleepiness and fatigue or when the RDI is ≥ 15 independently of the symptoms.
== Structure == The lamina propria is a loose connective tissue, hence it is not as fibrous as the underlying connective tissue of the submucosa. The connective tissue and architecture of the lamina propria is very compressible and elastic, this can be seen in organs that require expansion such as the bladder. The collagen in the lamina propria of elastic organs has been shown to play a major role in mechanical function. In the bladder the collagen composition of its lamina propria allows for structure, tensile strength, and compliance, through complex coiling. It has been suggested that myofibroblasts also reside in the lamina propria of several organs. These cells have characteristics of both smooth muscle and fibroblasts. The lamina propria may also be rich in vascular networks, lymphatic vessels, elastic fibers, and smooth muscle fascicles from the muscularis mucosae. Afferent and efferent nerve endings can be found in the lamina propria as well. Immune cells as well as lymphoid tissue, including lymphoid nodules and capillaries, may be present. Smooth muscle fibers may be in the lamina propria, such as in the intestinal villi. It is practically void of fat cells. Lymphatics penetrate the mucosa and lie below the basement membrane of the epithelium, from there they drain the lamina propria. The fast rate of cell death and regeneration of the epithelium leaves behind many apoptotic cell bodies. These have been found to go into the lamina propria, most of which are inside its macrophages.
== Synthesis == HMX is more complicated to manufacture than most explosives, and this confines it to specialist applications. It and RDX are both produced by the Bachmann process—nitration of hexamine using a mixture of ammonium nitrate and nitric acid in a mixture of acetic acid and acetic anhydride as solvent—with the major product determined by the specific reaction conditions.
== Reboot == At the London Film and Comic Con in July 2012, Garland said that a North American gross of over $50 million for Dredd would make sequels possible and that he had plans for a trilogy of films. A second film would focus on the origins of Dredd and Mega-City One, and a third would introduce Dredd's nemeses, the undead Judge Death and his Dark Judges. In August 2012, Garland said that a Judge Dredd television series would be a positive future step for the series. In September 2012, Garland said that he would explore the "Origins" and "Democracy" storylines, would introduce characters Judge Cal and Chopper, and would pursue the concept that Judge Dredd is a fascist. That same month, Macdonald said that further films would be made in partnership with IM Global and would likely be shot in South Africa. In March 2013, executive producer Adi Shankar said that a sequel was unlikely. In May 2013, Urban said that a sequel was still possible, noting that the film had found an audience, and the response of fans could resurrect the project. Dredd fans on Facebook launched a petition calling for a sequel. In July 2013, 2000 AD endorsed the fan petition, supporting the campaign by printing advertisements in their publications, and by September 2013 it had attracted over 80,000 signatures. In April 2013, 2000 AD released an image teasing a continuation of the film in comic book form with a release date scheduled for September 2013. The comic, titled Dredd: Underbelly, was made available in Judge Dredd Megazine #340 which was released on 18 September 2013.
=== Metabolic panel === A Metabolic Panel (MP) is a routine group of blood tests commonly used for health screenings, disease detection, and monitoring vital signs of hospitalized patients with specific medical conditions. MP panel analyzes common analytes in the blood to assess the functions of the kidneys and liver, as well as electrolyte and acid-base balances. There are two types of MPs - Basic Metabolic Panel (BMP) or Comprehensive Metabolic Panel (CMP).
Sources: en.wikipedia.org
The Central Dogma. This states that once "information" has passed into protein it cannot get out again. In more detail, the transfer of information from nucleic acid to nucleic acid, or from nucleic acid to protein may be possible, but transfer from protein to protein, or from protein to nucleic acid is impossible. Information here means the precise determination of sequence, either of bases in the nucleic acid or of amino acid residues in the protein. He re-stated it in a Nature paper published in 1970: "The central dogma of molecular biology deals with the detailed residue-by-residue transfer of sequential information. It states that such information cannot be transferred back from protein to either protein or nucleic acid." A second version of the central dogma is popular but incorrect. This is the simplistic DNA → RNA → protein pathway published by James Watson in the first edition of The Molecular Biology of the Gene (1965). Watson's version differs from Crick's because Watson describes a two-step (DNA → RNA / RNA → protein) process as the central dogma. While the dogma as originally stated by Crick remains valid today, Watson's version does not.
In 2001, a more complete juvenile tyrannosaur (nicknamed "Jane", accession number BMRP 2002.4.1), suggested to belong to the same species as the original Nanotyrannus specimen, was uncovered. This discovery prompted a conference on tyrannosaurs focused on the issues of the validity of Nanotyrannus, held at the Burpee Museum of Natural History in 2005. Several paleontologists who had previously published opinions that N. lancensis was a valid species, including Currie and Williams, saw the discovery of "Jane" as a confirmation that Nanotyrannus was, in fact, a juvenile T. rex. Peter Larson continued to support the hypothesis that Nanotyrannus lancensis was a separate but closely related species, and also argued that Stygivenator (LACM 28471), which is generally considered to be a juvenile of Tyrannosaurus rex, could be a younger specimen of Nanotyrannus. In 2011, news reports about a 2006 discovery of a new, virtually complete theropod specimen found alongside a ceratopsid were made. The specimens were studied by Robert Bakker and Peter Larson on-site, who identified the ceratopsian as Triceratops and the theropod as Nanotyrannus. It was impossible to determine whether the theropod specimen, nicknamed "Bloody Mary", was distinct from T. rex, as the specimen remained in private hands until 2020, when the ownership of the specimen was decided by the Montana Supreme Court to be given to the landowners Mary Anne and Lige Murray. The fossil was acquired by the North Carolina Museum of Natural Sciences in 2020.
== Epidemiology == In the United States, the incidence of osteogenesis imperfecta is estimated to be one per 20,000 live births. An estimated 20,000 to 50,000 people are affected by OI in the United States. The most common types are I, II, III, and IV, while the rest are very rare. Type I is the most common and has been reported to be around three times more common than type II. The prevalence of types III and IV is less certain. In a 1989 study in Denmark, type I was found to comprise 71% of cases and type II 12% of cases, with other types comprising the other 17%. In a 2015 study in Sweden, type I was nearly six times more common than type III and nearly four times more common than type IV. Most people with OI receive it from a parent, but in many cases, it is a brand new (de novo or "sporadic") mutation in a family. Among a study of patients with survivable types of OI, OI type III is most often de novo (85%), followed by type IV (50%) and type I (34%). Some populations can have a higher incidence of OI than would be otherwise expected if they have a larger-than-average number of carriers of the recessive forms of the disease.
=== Rabbit-skin glue === Rabbit-skin glue is more flexible when dry than typical hide glues. It is used in the sizing or priming of oil painters' canvases. It is also used in bookbinding and as the adhesive component of some recipes for gesso and compo.
Osteoporosis is a disease of bone where there is reduced bone mineral density, increasing the likelihood of fractures. Osteoporosis is defined in women by the World Health Organization as a bone mineral density of 2.5 standard deviations below peak bone mass, relative to the age and sex-matched average. This density is measured using dual energy X-ray absorptiometry (DEXA), with the term "established osteoporosis" including the presence of a fragility fracture. Osteoporosis is most common in women after menopause, when it is called "postmenopausal osteoporosis", but may develop in men and premenopausal women in the presence of particular hormonal disorders and other chronic diseases or as a result of smoking and medications, specifically glucocorticoids. Osteoporosis usually has no symptoms until a fracture occurs. For this reason, DEXA scans are often done in people with one or more risk factors, who have developed osteoporosis and are at risk of fracture. One of the most important risk factors for osteoporosis is advanced age. Accumulation of oxidative DNA damage in osteoblastic and osteoclastic cells appears to be a key factor in age-related osteoporosis. Osteoporosis treatment includes advice to stop smoking, decrease alcohol consumption, exercise regularly, and have a healthy diet. Calcium and trace mineral supplements may also be advised, as may Vitamin D. When medication is used, it may include bisphosphonates, Strontium ranelate, and hormone replacement therapy.
Sources: en.wikipedia.org
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.
Lyophilized powder is normally stored desiccated at -20 °C, protected from light and moisture. Powder kept under these conditions is generally stable for long periods. Solutions are less stable and are usually prepared immediately before use.
A purity value from one chromatographic method does not capture every possible impurity. Related peptides with similar retention behavior, counterions, and residual solvents may not appear in the same analysis. Independent testing with an orthogonal method provides stronger assurance of identity and content.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.